Correction to: Changes in Cataplexy Frequency in a Clinical Trial of Lower‑Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic Medications.

Autor: Dauvilliers Y; Sleep and Wake Disorders Centre, Department of Neurology, Gui de Chauliac Hospital, 80 Avenue Augustin Fliche, 34295, Montpellier, France. y-dauvilliers@chu-montpellier.fr.; University of Montpellier, INSERM Institute Neuroscience Montpellier (INM), Montpellier, France. y-dauvilliers@chu-montpellier.fr., Šonka K; Department of Neurology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic., Bogan RK; University of South Carolina School of Medicine, Columbia, SC, USA., Partinen M; Helsinki Sleep Clinic, Terveystalo Healthcare, Helsinki, Finland.; Department of Clinical Neurosciences, University of Helsinki, Helsinki, Finland., Del Rio Villegas R; Neurophysiology and Sleep Disorders Unit, Vithas Hospitals, Madrid, Spain., Foldvary-Schaefer N; Sleep Disorders Center, Cleveland Clinic, Cleveland, OH, USA., Skowronski R; Jazz Pharmaceuticals, Palo Alto, CA, USA., Chen A; Jazz Pharmaceuticals, Palo Alto, CA, USA., Black J; Jazz Pharmaceuticals, Palo Alto, CA, USA.; Stanford University Center for Sleep Science and Medicine, Redwood City, CA, USA., Skobieranda F; Jazz Pharmaceuticals, Philadelphia, PA, USA., Thorpy MJ; Albert Einstein College of Medicine, Bronx, NY, USA.
Jazyk: angličtina
Zdroj: CNS drugs [CNS Drugs] 2022 Jul; Vol. 36 (7), pp. 785-786.
DOI: 10.1007/s40263-022-00933-1
Databáze: MEDLINE